Peter Riches McIlroy

Title: The Innovations of Peter Riches McIlroy

Introduction

Peter Riches McIlroy is an accomplished inventor based in Livermore, CA. He has made significant contributions to the field of biotechnology, particularly in the development of nanobodies for combating SARS-CoV-2 variants. His innovative work has the potential to enhance therapeutic options in the fight against COVID-19.

Latest Patents

Peter Riches McIlroy holds a patent for "SARS-CoV-2 variant nanobodies and constructs comprising such nanobodies." This patent describes a large and highly diverse nanobody library that was constructed and screened against multiple variants of SARS-CoV-2. The research aimed to identify nanobodies with high sensitivity and specificity for various viral variants. Notably, at least 59 of these nanobodies were found to be effective against Alpha, Beta, Gamma, Delta, Kappa, Lambda, and Mu variants, with some overlap efficacy against other strains. The nanobodies have shown efficacy both as stand-alone entities and as constructs linked to the human IgG1 constant fragment, enhancing their half-life and optimizing effector functions.

Career Highlights

Peter is currently employed at National Technology & Engineering Solutions of Sandia, LLC, where he continues to innovate in the field of nanotechnology and biotechnology. His work has been pivotal in identifying promising nanobodies that neutralize the original SARS-CoV-2 and several of its variants, including Delta and Omicron, demonstrating high efficacy.

Collaborations

Peter has collaborated with notable colleagues, including Brooke Nicole Harmon and Le Thanh Mai Pham, contributing to the advancement of research in nanobody technology.

Conclusion

Peter Riches McIlroy's innovative work in developing nanobodies against SARS-CoV-2 variants showcases his significant contributions to biotechnology. His research not only addresses current health challenges but also paves the way for future advancements in therapeutic solutions.